Przegląd Dermatologiczny
facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Zeszyty specjalne Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
2/2025
vol. 112
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Opis przypadku

Dermatomyositis-Like Eruption Associated with Hydroxyurea Therapy

Katarzyna Winkel
1
,
Krzysztof Dobrzeniecki
1
,
Paweł Głuszak
1
,
Maciej Spałek
1
,
Dorota Jenerowicz
1

  1. Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
Dermatol Rev/Przegl Dermatol 2025, 112, 104–107
Data publikacji online: 2025/06/30
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Introduction:
Hydroxyurea is the first-line drug for patients with essential thrombocythemia in high-risk groups. Despite its relatively good tolerance, it can induce difficult-to-treat skin lesions.

Objective:
To present the case of a 64-year-old patient with an adverse reaction to long-term hydroxyurea therapy, described in the literature as “hydroxyurea-induced dermatomyositis-like eruption”.

Case report:
The patient with a 14-year history of essential thrombocythemia, treated with hydroxyurea, presented with hyperkeratotic lesions and bluish papules on the dorsa of the hands. Both antinuclear antibodies and dermatomyositis-associated antibodies were negative. Electromyographic examination prior to hospitalization was not indicative of primary damage to muscle cells. The result of the biopsy was consistent

Conclusions:
If a patient undergoing treatment with hydroxyurea develops a dermatomyositis-like eruption and topical treatment proves ineffective, change of the therapy should be considered.



© 2025 Termedia Sp. z o.o.
Developed by Bentus.